Comparative Pharmacology
Head-to-head clinical analysis: LUMIGAN versus TRAVATAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIGAN versus TRAVATAN.
LUMIGAN vs TRAVATAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a prostamide analog that selectively mimics the effects of prostamide F2α, activating prostaglandin F (FP) receptors. It increases aqueous humor outflow through the uveoscleral pathway and may also enhance trabecular outflow, reducing intraocular pressure.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix in the ciliary body.
One drop of 0.01% ophthalmic solution in the affected eye(s) once daily in the evening.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 78 minutes (range 54-102 minutes) in plasma after ocular administration. This short half-life reflects rapid systemic clearance, but ocular tissue levels persist longer due to local tissue binding.
Terminal elimination half-life is approximately 45 minutes for travoprost acid (active metabolite). Clinical context: due to rapid systemic clearance, ocular hypotensive effect persists for 24 hours from corneal tissue binding.
Primarily via renal elimination (approximately 67% of administered dose excreted in urine as metabolites, with less than 1% as unchanged drug). The remainder is excreted in feces (approx. 25%) via biliary elimination.
Renal (primarily as metabolites): ~70%; Fecal: ~25%; Unchanged drug in urine: <1%
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog